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The eosinophil cell has been related as a prognostic indicator for cancers. However, its exact function in tumour behaviour is still
not clearly deﬁned. In the oral cavity the presence of eosinophils can be a favourable prognostic indicator as well as it may be
associated with a poor prognosis. In this short review, we brieﬂy summarize the role of the eosinophils in the general context of
immunoregulation and its relation to oral squamous cell carcinoma.
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1.Introduction
The vast majority of cancers in the oral cavity are squamous
cell carcinomas (SCC)—its evolution is inﬂuenced by host
immune response cells (e.g., CD8+ T, CD4+ T, natural killer
cells-NK, dendritic cells-DC, macrophages, and eosinophils)
[1].
The eosinophils are considered as destructive eﬀector
leukocytes with cytotoxic activities mainly implicated in
parasitic infections (e.g., helminthic infections) and allergic
diseases (e.g., bronchial asthma, allergic dermatitis, etc.).
However, studies have shown that they can also be involved
in tissue remodelling and in innate and acquired immunity
response modulation [2, 3]( Figure 1).
Under diverse stimuli (e.g., infections, tumours, etc.),
the eosinophils are able to release diﬀerent substances, such
as, eosinophil cationic protein (ECP), major basic protein
(MBP), eosinophil peroxidise (EPO), eosinophil-derived
neurotoxin (EDN), IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12, IL-13, IL-18, interferon (INF)-γ, tumor necrosis
factor (TNF)-α, transforming growth factor (TGF)-α,T G F -
β, chemokines (RANTES, endotaxin-1), platelet-activating
factor (PAF), leukotriene C4 (LTC4), neuromediators, and
indoleamine 2,3-dioxygenase (IDO) [4, 5]. These substances
may cause cell death and induction of inﬂammatory
symptoms as well as contribute to tumour progression or
regulation. Furthermore, the eosinophils present membrane
receptors (e.g., IL-1, 3, 4, 5, 8, 10, 12, 13, granulocyte mono-
cyte colony-stimulating factor—GM-CSF, IFN-γ,T N F - α,
and macrophage inﬂammatory protein-1α) that confer a
survival and recruitment capacity of eosinophils themselves
[2].
In oral SCC, the exact function of eosinophils still
remains unclear. Several studies have shown that eosinophils
can be associated with an improved prognosis, but there are
other studies however, showing their association with a poor
p r o g n o s i sa sw e l l[ 6, 7].
In this short review, we summarize brieﬂy the role of the
eosinophils in the general context of immunoregulation and
its relation with oral squamous cell carcinoma.
2 .T h eE o s i n o p h i la n dI t sD i v e r s eF u n c t i o n si n
the Context of Immunoregulation
Under a speciﬁc stimulus, the na¨ ıve CD4+ T and CD8+ Tc e l l
can be diﬀerentiated, respectively, into Th2 and Tc2 cells and
secrete mainly cytokines involved with humoral immunity
such as IL-4, IL-5, IL-10, and IL-13 [8, 9]. The initial recruit-
ment and activation of eosinophils towards the tumour
microenvironment is principally related with Th2 response,
although necrotic cells can stimulate both the migration2 Journal of Oncology
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Figure 1: Eosinophil function in the immune response. The eosinophils can stimulate or inhibit the immune response, leading to a
probable good or poor prognosis, respectively. EPO: Eosinophil peroxidase; MBP: Major basic protein; ECP: Eosinphil cationic protein;
EDN: Eosinophil-derived neurotoxin; IL (Interleukin)-4, IL5, IL-10, IL-12, IL-13; IFN-γ: Interferon-γ; MHC II: histocompatibility complex
II molecules; IDO: indoleamine 2, 3-dioxygenase; TGF-β: Transforming growth factor-β.
and the activation of eosinophils [10, 11]. According to the
literature, Th2 response may eliminate the cancer on the
dependence of eosinophils and macrophages [8, 12–14]. IL-
4 and IL-13 are potent inducers of eotaxin chemokines that
can explain the eosinophilia associated with Th2 responses
[15]. In oral squamous cell carcinoma, the eotaxin expressed
by tumour cells and eosinophils were involved in the
mechanisms of eosinophil chemotaxis to the tumour [16].
IL-4 presents antiangiogenic properties which could inhibit
the tumour growth [17]. Furthermore, IL-5 transgenic mice
presented attenuated growth of ﬁbrosarcoma induced by
methylcholanthrene [18]. However, IL-4 can have a cell
antiapoptotic property which could help tumour growth
[19]. IL-13 has also been involved with the antitumour
immune response mediated mainly by neutrophils (Gr-
1+) and macrophages (MAC-3+)[ 20]. However, IL-13 can
also inhibit the IFN-γ secretion and CD8+ cytotoxic T
lymphocyte(CTL)activityandcompromisetheanti-tumour
immunity response [21].
Studies have also shown that eosinophils can process
and present histocompatibility complex II (MHC-class
II) molecules [22] and polarize the Th2 response [23].
Upon stimulation with IFN-γ,I L - 3 ,a n dG M - C S F ,h u m a n
eosinophilc cell line diﬀerentiated with dibutyryl cyclic AMP
(dEoL-1)andhumanperipheralblood(PB)eosinophilswere
able to respond to the lymphoid chemokines (e.g., CCL11,
CCL21, and CCL25). In addition, cytokine-stimulated
dEoL-1 cells expressed human leukocyte antigen (HLA)-
DR and costimulatory molecules such as CD80, CD86 and
CD40 [24]. Therefore, eosinophils can migrate to the lym-
phoid chemokine microenvironment and express antigen-
presenting cells (APCs)- related costimulatory molecules.
However, some experimental models have suggested that
eosinophils are ineﬃcient antigen-presenting cells when
compared to macrophages [25] or dendritic cells [26].
The eosinophil-derived neurotoxin stored in eosinophils
granules is able to induce DC maturation and activation
through up-regulation of mitogen-activated protein (MAP)
kinases, nuclear factor-Kappa B (NF Kappa B) and CD83,
CD86 costimulatory molecules, and MHC class II expression
[27, 28]. EDN-treated human DCs stimulated Th2 immune
response via Toll-like receptor (TLR)2-MyD88 signal [28].
Eosinophils can also be related with cytokines of Th1
response [29]. They may express IFN-γ as well as IL-4, IL-5
and IL-10 suggesting a subpopulation of human eosinophils
that expresses Th1 or Th2 cytokines, respectively [30]. It has
been shown that not only the Th1 response is able to eradi-
cate the tumour through the cellular immunity response but
also Th2 response via tumour necrosis [12]. Furthermore,
IL-12 expressing eosinophils are able to activate Th1 [31].
Contrarily, eosinophils are capable to downregulate the
antitumour immunity, through mainly IL-10 [32]a n d
IDO production [33]. IL10 is a potent inhibitor of MHC
complex and CD80 and CD86 expression on DC as well
as it suppresses the DC diﬀerentiation. In addition, IL-10
prevents the Th1 and Th2 cytokines production. Contrarily,
IL-10canplayaroleintheBcellactivationandsurvival[32].
Through indoleamine 2,3-dioxygenase production, the
eosinophils may also play a role in escape immune surveil-
lance. This enzyme catalyzes the amino acid tryptophan
to kynurenine which is able to cause cycle arrest and
apoptosis from uncommitted CD4+ T cells [33]a sw e l la s
maintenance of Th2 response [34]. The IDO was correlated
with the poor prognosis in the non-small cell lung cancer
[35].
It has been shown that the eosinophils are capable
of producing various substances (e.g., vascular endothelial
growth factor-VEGF, ﬁbroblast growth factor-FGF, TNF-
α, GM-CSF, nerve growth factor-NGF, TGF-β, and IL-8)
that can promote angiogenesis and produce collagenous
ﬁbers [36]. In addition, TGF-β is considerate as a strong
immunosuppressive cytokine—it is capable of inhibiting T
cell proliferation and diﬀerentiation. TGF-β can also inhibit
the cytolytic activity of NK [37].Journal of Oncology 3
3.PrognosticValueof EosinophilsinOral
SquamousCellCarcinoma
In head and neck SCC, it has been shown that the Th1
response is mainly associated with a better prognosis than
those with the Th2 response [38, 39]. According to Argarwal
and colleagues [40], early stage of oral SCC expressed mainly
INF-γ andIL-2genes(Th1responses),whereastheadvanced
stage tumours presented IL-4 and IL-10 expression (Th2
response). In addition, advancing lesions of the tongue
squamous cell carcinoma, induced by 4-nitroquinoline-1-
oxide, have downregulated Th1-type and upregulated Th2-
type cytokine production [41].
Regarding studies with eosinophils in the blood, the
presence of eosinophils and Th2 cells can be related with
tumour progression [42] and poor prognosis [43, 44].
Peripheral blood analyses of intraoral squamous cell car-
cinoma with a history of tobacco use presented enhanced
expression of Th2 cytokine [43]. The metastatic squamous
cell carcinoma showed increased blood eosinophilia and
elevated serum interleukin-5 levels [44]. However, patients
with malignant disease (e.g., acute lymphoblastic leukemia,
acute myelogenous leukemia) that underwent stem cell
transplantation [45] or patients with cervical cancer treated
with whole-pelvic irradiation [46] presented increased blood
eosinophilia and better overall survival.
Tumour-associated tissue eosinophilia (TATE) has been
reported in diverse sites [14, 35, 47–53] including the head
and neck region [6, 7, 54–65]( Figure 2).
In the head and neck region, TATE presents controversial
results. Some studies have shown that the TATE has a
favourable prognosis, suggesting that eosinophils may play
a protective role against epithelial tumours [6, 55, 60, 62].
Other studies however, suggest that eosinophils may play a
role in promoting epithelial tumour growth accounting for
ap o o rp r o g n o s i s[ 7, 57, 58]o re v e nn oe ﬀect on tumour
evolution [54, 56, 59, 63].
With regard to good prognosis, it has been shown
that oral SCC patients with TATE presented higher overall
survival [6] and less incidence of distant metastasis in head
and neck tumours [62]. Nevertheless, Tadbir and colleagues
[54] have shown that TATE was not associated with vascular,
perineural, muscle invasion, and locoregional metastasis in
SCC of the oral cavity. Similar results were observed in
nasopharyngeal carcinoma [56] and oral SSC [65]w h e r e
the eosinophils were not associated with local recurrence,
distant metastases, or survival. In another study of laryngeal
squamous cell carcinoma, TATE was associated only with
the age-TATE-positive patients presented between 50 and
60 years of age, whereas the TATE-negative patients were
between 60 and 70 years of age [63]. According to Oliveira
and colleagues [65] and Cormier and colleagues [11], the
presence of eosinophis in damaged striated muscular ﬁbers
of oral cancer or in capsule of B16-F10 melanoma cell-
derived tumours, respectively, could be related with tissue
remodelling.
On the other hand, the presence of eosinophils has also
been related with a poor prognosis. In oral SCC, eosinophilic
inﬁltration and HLA-DR expression in tumour cells were
Figure 2: Oral squamous cell carcinoma showing rather numerous
eosinophils (black arrows), together with lymphocytes, mingling
around nests of nonkeratinized neoplastic oral epithelial cells.
Formalin-ﬁxed, paraﬃn embedded tissue, H&E stained, original
magniﬁcation ×400.
related to unfavourable prognosis [7]. In the experimental
studies of oral carcinoma, the depletion of TATE with anti-
IL-5 mAb was associated with a delayed development of the
tumours [64]. According to Falconieri and colleagues [61]
and Oliveira and colleagues [65], the eosinophil presence
in the SCC of the oral cavity was associated with stromal
invasion and metastasis [61]. Similar results have been
observed in head and neck carcinoma [57, 58] and cervix
[51] where eosinophils inﬁltrate has increased the suspicion
of invasion. The presence of >3 eosinophils/high-power ﬁeld
(hpf), ≥5/hpf, and ≥10/10hpf in cervical incisional biopy
and excisional specimens were associated with invasion [51].
According to Dorta and colleagues [6], the prognosis
related with TATE is controversial due to the diﬀerent
methodology utilized to count tumour-associated tissue
eosinophila, thereby prejudicing a comparison of the results.
For this reason Alkhabuli and High [66] suggested the
counting of eosinophils through a density method, which
utilizes the highest density of eosinophils per surface area, in
preference to the classic method that counts eosinophils/hpf.
4. Conclusion
In general, the presence as well as the state of activation
of immunologic cells plays an important role in tumour
cell progression. Diverse studies examining eosinophils in
tumour development have been carried out. However, the
prognostic value of eosinophils in oral carcinoma still
remains unclear. Further studies on eosinophils and their
state of activation are necessary in order to elucidate these
ﬁndings.
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